New developments in antifungal strategy

References

• Martin GS, Mannino DM, Eaton S, Moss M. The epidemiology of sepsis in the United States from 1979 through 2000. N Engl. J. Med. 348, 1546–1554 (2003).
   PubMed Web of Science ®Google Scholar
• BSMM Mycology Training Working Party Medical Mycology in the UK. Manpower crisis threatens the future of UK medical mycology Commun. Dis. Public Health 3, 80–81 (2000).
   PubMedGoogle Scholar
• Ascioglu S, Rex JH, Pauw B, et al. Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. Clin. Infect. Dis. 34, 7–14 (2002).
   PubMed Web of Science ®Google Scholar
• •• Describes the standard definitions of invasive fungal infections based on host, clinical manifestations and microbiological factors.
   Google Scholar
• Kami M, Kishi Y, Hamaki T, et al. The value of the chest computed tomography halo sign in the diagnosis of invasive pulmonary aspergillosis. An autopsy-based retrospective study of 48 patients. Mycoses 45, 287–294 (2002).
   PubMed Web of Science ®Google Scholar
• Muller FM, Trusen A, Weig M. Clinical manifestations and diagnosis of invasive aspergillosis in immunocompromised children. Eur. j Paed 161, 563–574 (2002).
   PubMed Web of Science ®Google Scholar
• Subira M, Martino R, Rovira M, et al. Clinical applicability of the new EORTC/MSG classification for invasive pulmonary aspergillosis in patients with hematological malignancies and autopsy confirmed invasive aspergillosis. Ann. HematoL 82, 80–82 (2003).
   PubMed Web of Science ®Google Scholar
• Hebart H, Loffler J, Meisner C, et al. Early detection of Aspergillus infection after allogenic stem cell transplantation by polymerase chain reaction screening. J. Infect. Dis. 181, 1713–1719 (2000).
   PubMed Web of Science ®Google Scholar
• Kawamura S, Maesaki S, Noda T, et al. Comparison between PCR and detection of antigen in sera for diagnosis of pulmonary aspergillosis. J. Clin. Microbial. 37, 218–220 (1999).
   PubMed Web of Science ®Google Scholar
• Bowden R, Chandrasekar P, White MH, et al. A double-blind, randomized, controlled trial of amphotericin B colloidal dispersion versus amphotericin B for treatment of invasive aspergillosis in immunocompromised patients. Clin. Infect. Dis. 35, 359–366 (2002).
   PubMed Web of Science ®Google Scholar
• Rogers PD, Barker KS, Herring V, et al. Heat-induced superaggregation of amphotericin B attenuates its ability to induce cytokine and chemokine production in the human monocytic cell line THP-1. Antimicrob. Chemother. 51, 405–408 (2003).
   Google Scholar
• Eriksson U, Seifert B, Schaffner A. Comparison of effects of amphotericin B deoxycholate infused over 4 or 24 hours: randomized controlled trial. Brit. Med. J. 322, 579–582 (2001).
   PubMed Web of Science ®Google Scholar
• Imhof A, Walter RB, Schaffner A. Continuous infusion of escalated doses of amphotericin B deoxycholate: an open label observational study. Clin. Infect. Dis. 36, 943–951 (2003).
   PubMed Web of Science ®Google Scholar
• DeBeule K, Van Gestel J. Pharmacology of itraconazole. Drugs 61\(Suppl. 1), 27–37 (2001).
   Google Scholar
• Morgenstern GR, Prentice AG, Prentice HG, Ropner JE, Schey SA, Warnock DW. A randomized controlled trial of itraconazole versus fluconazole for the prevention of fungal infections in patients with hematological malignancies. Brit. J. HaematoL 105, 901–911 (1999).
   PubMed Web of Science ®Google Scholar
• Boogaerts M, Winston DJ, Bow EJ, et al. Intravenous and oral itraconazole versus intravenous amphotericin B deoxycholate as empirical antifungal therapy for persistent fever in neutropenic patients with cancer who are receiving broad-spectrum antibacterial therapy. Ann. Intern. Med. 135, 412–422 (2001).
   PubMed Web of Science ®Google Scholar
• Chandrasekar PH, Manavathu E. Voriconzole: a second generation triazole. Drugs Today 37, 135–148 (2001).
   PubMed Web of Science ®Google Scholar
• Johnson LB, Kauffman CA. Voriconazole: a new triazole antifungal agent. Clin. Infect. Dis. 36, 630–637 (2003).
   PubMed Web of Science ®Google Scholar
• •• A good review article on voriconazole.
   Google Scholar
• Romero AJ, Le Pogamp P, Nillison L-G, Wood N. Effect of voriconazole on the pharmacokinetics of cyclosporine in renal transplant patients. Clin. Pharmac.Ther. 71, 226–234 (2002).
   PubMed Web of Science ®Google Scholar
• Venkataramanan R, Zang S, Gayowski T, Singh N. Voriconazole inhibition of the metabolism of tacrolimus in a liver transplant recipient and in human liver microsomes. Antimicrob. Agents Chemother. 46, 3091–3093 (2002).
   PubMed Web of Science ®Google Scholar
• Walsh TJ, Pappas P, Winston DJ, et al. Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever. N EngL J. Med. 346, 225–234 (2002).
   PubMed Web of Science ®Google Scholar
• Herbrecht R, Denning DW, Patterson TF, et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N EngL J. Med. 347, 408–415 (2002).
   PubMed Web of Science ®Google Scholar
• Troke PF, Schwartz S, Ruhnke M, et al. Voriconazole therapy in 86 patients with CNS aspergillosis: a retrospective analysis. 43rd ICAAC abstracts. Am. Soc. MicrobioL. M-1755, 476 (2003) (Abstract).
   Google Scholar
• Lortholary O, Mouas-Dupuy H, Dupont B, Lutsar I, Fain O. Voriconazole for bone aspergillosis: a worldwide experience of 19 cases. 43rd ICAAC abstracts. Am. Soc. MicrobioL M-979, 450 (2003) (Abstract).
   Google Scholar
• Ally R, Schurmann D, Kreisel W, et al. A randomized, double-blind, double-dummy, multi-center trial of voriconazole and fluconazole in the treatment of esophageal candidiasis in immunocompromised patients. Clin. Infect. Dis. 33, 1447–1454 (2001).
   PubMed Web of Science ®Google Scholar
• Neely MN, Ghannoum MA. The exciting future of antifungal therapy. Eur J. Clin. MicrobioL Infect Dis. 19, 897–914 (2000).
   PubMed Web of Science ®Google Scholar
• Greenberg RN, Anstead G, Herbrecht R, et al. Posaconazole experience in the treatment of zygomycosis. 43rd ICAAC abstracts. Am. Soc. MicrobioL M-1757, 476 (2003) (Abstract).
   Google Scholar
• Ullmann AJ, Comely 0 A, Burchardt A, et al. Safety and efficacy of posaconazole (pos) in a pharmacokinetic study in patients with febrile neutropenia (FN) or refractory invasive fungal infections (RIFT). 43rd ICAAC abstracts. Am. Soc. MicrobioL M-1257, 474 (2003) (Abstract).
   Google Scholar
• Kartsonis N, Dinubile MJ, Bartizal K, et al. Efficacy of caspofungin in the treatment of esophageal candidiasis resistant to fluconazole. J. Acquir. Immun. Defic. Syndr. 31, 183–187 (2002).
   PubMed Web of Science ®Google Scholar
• Mora-Duarte J, Betts R, Rotstein C, et al. Comparison of caspofungin and amphotericin B for invasive candidiasis. N EngL J. Med. 347, 2020–2029 (2002).
   PubMed Web of Science ®Google Scholar
• Kartsonis N, Saah A, Lipka J, Taylor A, Sable C. Salvage therapy with caspofungin for invasive aspergillosis (IA): results from the CAS compassionate use study. 43rd ICAAC abstracts. Am. Soc. MicrobioL M-981, 451(2003) (Abstract).
   Google Scholar
• Maertens J, Raad I, Petrikkos G, et al. Update of the multicenter noncomparative study of caspofungin (CAS) in adults with invasive aspergillosis (IA) refractory (R) or intolerant (I) to other antifungal agents: analysis of 90 patients. 42nd ICAAC abstracts. Am. Soc. MicrobioL (2002) (Abstract M–868).
   Google Scholar
• Walsh T, Sable C, De Pauw B, et al A randomized, double-blind, multicenter trial of caspofungin vs. liposomal amphotericin B for empirical antifungal therapy of persistently febrile neutropenic patients. 43rd ICAAC abstracts. Am. Soc. MicrobioL M-1761, 477 (2003) (Abstract).
   Google Scholar
• Van Burik J, Ratanatharathorn V, Lipton J, et al. Randomized double blind trial of micafunginversus fluconazole for prophylaxis of invasive fubgal infection in patients undergoing hematopoietic stem cell transplant. 42nd ICAAC abstracts. Am. Soc. MicrobioL (2002) (Abstract 1238).
   Google Scholar
• Ullmann AJ, Van Burik JA, McSweeney P, et al. An open Phase II study of the efficacy of micafungin (FK463) alone and in combination for the treatment of invasive aspergillosis (IA) in adults and children. 13th Eur. Congress Clin. MicrobioL Infec. Dis. Abstracts (2003) (Abstract 0400).
   Google Scholar
• Krause D, Goldstein B, Wible M, Kilfoil G, Henkel T. A Phase II-dose ranging study of the safety and efficacy of anidulafungin in invasive candidiasis. 13th Eur. Congress Clin. MicrobioL Infec. Dis. Abstracts (2003) (Abstract 403).
   Google Scholar
• Martinez A, Aviles P, Jimenez E, Caballero J, Gargallo-Viola D. Activities of sordarins in experimental models of candidiasis, aspergillosis, and pneumocystosis. Antimicrob. Agents Chemother. 44, 3389–3394 (2000).
   PubMed Web of Science ®Google Scholar
• Rex JH, Walsh TJ, Sobel JD, et al. Practice guidelines for the treatment of candidiasis. Clin. Infect. Dis. 30, 662–678 (2000).
   PubMed Web of Science ®Google Scholar
• Mayanja-Kizza H, Oishi K, Mitarai S, et al. Combination therapy with fluconazole and flucytosine for cryptococcal meningitis in Ugandan patients with AIDS. Clin. Infect. Dis. 26, 1362–1366 (1998).
   PubMed Web of Science ®Google Scholar
• Lewis RE, Kontoyiannis DR Rationale for combination antifungal therapy. Pharmacotherapy 21, S149—S164 (2001).
   Google Scholar
• •Informative review describing the principles of antifungal drug combinations and the problems surrounding antifungal susceptibility testing.
   Google Scholar
• Lewis RE, Lund BC, Klepser ME, Ernst EJ, Pfaller MA. Assessment of antifungal activites of fluconazole and amphotericin administered alone and in combination against a C albicans using a dynamic in vitro mycotic infection model. Antimicrob. Agents Chemother. 42, 1382–1386 (1998).
   PubMed Web of Science ®Google Scholar
• Rex JH, Pappas PG, Karchmer AW, et al. A randomized and blinded multicenter trial of high-dose fluconazole plus placebo versus fluconazole plus amphotericin B as therapy for candidemia and its consequences in nonneutropenic subjects. Chu. Infect. Dis. 36, 1221–1228 (2003).
   PubMed Web of Science ®Google Scholar
• Kontoyiannis DP, Hachem R, Lewis RE, et al. Efficacy and toxicity of caspofungin in combination with liposomal amphotericin B as primary or salvage treatment of invasive aspergillosis in patients with hematologic malignancies. Cancer 98, 292–299 (2003).
   PubMed Web of Science ®Google Scholar
• Arikan S, Lozano-Chiu M, Paetznick V, Rex JH. In vitro synergy of caspofungin and amphotericin B against Aspergillus and Fusarium spp. Antimicrob. Agents Chemother. 46, 245–247 (2002).
   PubMed Web of Science ®Google Scholar
• Romani L. Host immune reactivity and antifungal chemotherapy: the power of being together. J. Chemother. 13, 347–353 (2001).
   PubMed Web of Science ®Google Scholar
• •Overview of immune response to fungal infection highlighting the potential for immunotherapy in combination with antifungal agents.
   Google Scholar
• Mencaci A, Cenci E, Bacci A, Bistoni F, L Romani. Host immune reactivity determines the efficacy of combination immunotherapy and antifungal chemotherapy in candidiasis. J. Infect. Dis. 181, 686–694 (2000).
   PubMedGoogle Scholar
• Oncology Association. Update of recommendations for the use of hematopoietic colony stimulating factors: evidence-based clinical practice guidelines. J. Clin. OncoL 14, 1957–1960 (1996).
   PubMedGoogle Scholar
• Volpi I, Perruccio K, Tosti A, et al. Postgrafting administration of granulocyte colony-stimulating factor impairs functional immune recovery in recipients of human leukocyte antigen haplotype-mismatched hematopoietic transplants. Mood 97, 2514–2521 (2001).
   Google Scholar
• Poynton CH, Barnes RA, Rees J. Interferon-y in the treatment of deep-seated fungal infection in acute leukemia. Clin. Infect. Dis. 26, 239–240 (1998).
   PubMed Web of Science ®Google Scholar
• Cenci E, Mencacci A, Del Sero G, Bistoni F, Romani L. Induction of protective Thl responses to Candida albicans by antifungal therapy alone or in combination with an Interleukin-4 antagonist. J. Infect. Dis. 176, 217–226 (1997)
   Google Scholar
• Kibbler CC, Seaton S, Barnes RA, et al. Management and outcome of bloodstream infections due to Candida species in England and Wales. J. Hosp. Infect. 54, 18–24 (2003).
   PubMed Web of Science ®Google Scholar
• Hegener P, Troke P, Fatkenheuer G, Diehl V, Ruhnke M. Treatment of fluconazole-resistant candidiasis with voriconazole in patients with AIDS. AIDS 12, 2227–2228 (1998).
   PubMed Web of Science ®Google Scholar
• Villaneuva A, Arathoon EG, Gotuzzo E, Berman RS, DiNubile MJ, Sable CA. A randomized double-blind study of caspofungin versus amphotericin for the treatment of candidal esophagitis. Clin. Infect. Dis. 33, 1529–1535 (2001).
   PubMedGoogle Scholar
• Arathoon EG, Gotuzzo E, Noriega LM, Berman RS, DiNubile MJ, Sable CA. Randomized, double-blind, multicenter study of caspofungin versus amphotericin B for treatment of oropharyngeal and esophageal candidiases. Antimicrob. Agents Chemother. 46, 451–457 (2002).
   PubMed Web of Science ®Google Scholar
• Mattiuzzi GN, Kantarjian H, Alvarado G. Intravenous itraconazole (ITRA) versus caspofungin (CASPO) prophylaxis in patients (PTS) with acute myelogenous leukaemia (AML) and myelodysplastic syndrome (MDS) undergoing induction chemotherapy (IC). 43rd ICAAC Abstracts. Am. Soc. Microb. M-984, 451 (2003) (Abstract).
   Google Scholar
• Krause DS, Henkel T, Goldstein BE Walsh TJ. Anidulafungin vs. fluconazole in esophageal candidiasis: a Phase III, randomized, double-blind, multicenter trial. 43rd ICAAC Abstracts. Am. Soc. Microb. (2003) (Abstract M–1760).
   Google Scholar